Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer
Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer
About this item
Full title
Author / Creator
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
6 years have passed since Matthew Hellman and colleagues 1 proposed major pathological response as a surrogate endpoint of survival for patients undergoing neoadjuvant therapy for operable lung cancer. Even disease-free survival is increasing in complexity as a measure of efficacy, with what constitutes being disease free rapidly evolving through b...
Alternative Titles
Full title
Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2557544394
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2557544394
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(21)00405-8
